

Reprint # 39-05

Drug Reimportation Survey Results

By John Mack

“Show me the dead Canadians. Where are the dead Canadians?”

-- Republican Minnesota Gov. Tim Pawlenty

Minnesota, as well as other states, have established Web sites helping their citizens find Canadian pharmacies deemed reputable and safe by state officials.

In 2002, the American people imported about \$1.1 Billion worth of drugs from Canada. It's a growing and real concern for the pharmaceutical industry. To add to the industry's woes, Congress is considering several bills that seek to make drug importation from Canada legal (see article, "Congress Fiddles While Reimportation Issue Burns," PMN Reprint 38-02).


Pharma Marketing News recently conducted a survey, which asked subscribers whether or not they agreed with the following arguments often used against reimportation:

- Terrorists may target imported drugs
- Risk of endangering patients with counterfeit or substandard drugs
- No guarantee reimported drugs would be cheaper after middlemen get their cut
- FDA cannot guarantee safety of reimported drugs
- Proposed reimportation programs are too complex and expensive
- Would hinder the ability of pharmaceutical companies to invest in R&D for new drugs

The results are summarized in the following chart, in which a numerical average is calculated representing how strongly respondents agreed or disagreed with each of the above arguments.

Safety Issue

Obviously, some state officials like Governor Pawlenty think they can assure the safety of drugs imported from Canada, whereas the FDA and PhRMA have consistently warned about assuring safety.



Respondents to our survey also cited safety as the major concern. Fifty-four percent (54%) of all respondents and 100% of pharma respondents agree or strongly agree that FDA cannot guarantee the safety of reimported drugs. One respondent said: "No one can guarantee the safety of anything. Much of the current backlash arises from contradictory messages: DTC that implies the drug-taking decision is trivial vs. reimportation rhetoric that characterizes the stakes as life and death."

Sen. Olympia Snowe (R-Maine), a sponsor of The Pharmaceutical Market Access and Drug Safety Act of 2004, a bipartisan bill that would allow the importation of prescription drugs, has said, "If European countries can safely trade prescription drugs, the United States should be up to the task as well."

R&D Issue

The second most cited argument against reimportation was its supposed negative effect on R&D expenditures. Fifty-one percent (51%) of all respondents and 57% of pharma respondents agree or strongly agree that allowing widespread reimportation would hinder the ability of pharmaceutical companies to invest in R&D for new drugs.

“Reimportation is a stalking horse for price controls,” said a respondent. “If the last free market for prescription drugs is enslaved, public health will be ruinously harmed by capital flight and the abortion of undiscovered therapies for life threatening diseases.”

“It could put smaller companies that specialise in making drugs for rare diseases out of business and severely hinder the orphan drug program,” according to another respondent. However, a third respondent claimed that “reimportation might drive more R&D to niche products and for acute conditions.”

Counterfeit Issue

The majority of respondents (54%) disagrees or strongly disagrees that there is a risk of endangering patients with counterfeit or substandard drugs (compared to 43% of pharma respondents who felt this way).

As one respondent remarked: “Aren't sub-standard drugs already available in the US? Why are products recalled periodically?”

Making Reimportation Legal

As mentioned, several bills are before Congress that would legalize reimportation of drugs from Canada and other countries. Even president Bush concedes that the idea is worth a try “if there's a safe way to do it.”

The majority (60%) of respondents declared that they are no familiar with these bills, while 34% agreed or strongly agreed that the programs proposed by the bills are too complex and expensive.

Thanks to everyone who answered our survey.

Pharma Marketing News

Pharma Marketing News

Pharma Marketing News—the First Forum for Pharmaceutical Marketing Experts—is published monthly by **VirSci Corporation** except for August. It is distributed electronically by email and the Web to members of the Pharma Marketing Network (www.pharmamkting.com).

VirSci Corporation specializes in pharmaceutical marketing intelligence and best practices, development of sponsored newsletters and other educational programs, and consulting in privacy and HIPAA. Our goal is to help our clients gain access to *their* clients and do business via the Internet more effectively, with greater return on

Publisher & Executive Editor

John Mack
VirSci Corporation
www.virsci.com
PO Box 760
Newtown, PA 18940
215-504-4164, 215-504-5739 FAX
<mailto:editor@pharmamarketingnews.com>

Advisory Board

Jack Pfister
Director, Business Development, Bruce Leeb & Company

Harry Sweeney
Chairman, CEO, Dorland Global Health Communications

Richard Vanderveer, PhD
Chairman & CEO, V2 GfK

Subscribe to Pharma Marketing News

Pharma Marketing News (PMN) is the FREE monthly e-newsletter of the **Pharma Marketing Network**. Each month, except August, an executive summary of the newsletter with links to the full text pdf version is delivered to subscribers by e-mail. By subscribing to PMN, you agree to receive additional occasional promotional e-mail messages as well as newsletter highlights. If you do not wish to receive any promotional e-mail messages but would rather pay a small fee for full text reprints of selected individual articles, please check **REPRINT NOTIFICATION SERVICE** as your option below. Through the Reprint Notification service, you receive only one monthly executive summary (no separate promotional messages) by e-mail with information about ordering the full-text versions of articles. We do not sell or share your personal information with third parties.

RED=REQUIRED INFORMATION

[CLICK HERE FOR ONLINE SUBSCRIPTION FORM](#)

FIRST NAME: _____ LAST NAME: _____

JOB TITLE: _____ COMPANY: _____

COUNTRY: _____

E-MAIL ADDRESS: _____

E-MAIL FORMAT PREFERENCE: ___ HTML ___ TEXT ___ NONE

SUBSCRIBE ME TO THE REPRINT NOTIFICATION SERVICE ONLY!

I understand that I will receive only one (1) e-mail message per month with information about ordering, for a low fee, selected article reprints (electronic pdf files) from the current issue of the newsletter. I have no obligation to order or pay for any reprint whatsoever.

THE FOLLOWING INFORMATION IS OPTIONAL (For our internal use only. We do not sell or rent this information to third parties)

ADDRESS: _____

CITY: _____ STATE/PROV: _____ POSTAL CODE: _____

PHONE: _____ FAX: _____

Mail or fax to: VirSci, PO Box 760, Newtown, PA 18940, 215-504-5739 (Fax)